Bijan Boldajipour

Lyell Immunopharma (United States) — United States

Medicine · Health Sciences

16h-index3.9kcitations35works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(21), Immunotherapy and Immune Responses(12), Viral Infectious Diseases and Gene Expression in Insects(9), Nanowire Synthesis and Applications(5), T-cell and B-cell Immunology(4)

Publications35 total

Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation
Scientific Reports·2024· 5 citedOpen Access
Abstract 4067: Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity
Cancer Research·2024
1047 Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
Regular and Young Investigator Award Abstracts·2023Open Access
Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
Supplementary Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
Supplementary Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
185 Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity
Regular and Young Investigator Award Abstracts·2022Open Access
252 Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R<sup>TM</sup> technology, a programmable synthetic cell-signaling platform
Regular and Young Investigator Award Abstracts·2022Open Access
232 Increased potency and functional persistence <i>in vitro</i> of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
Regular and Young Investigator Award Abstracts·2022Open Access
Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
Cancer Immunology Research·2022· 7 citedOpen Access
Abstract 2754: LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors
Cancer Research·2022· 4 cited
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Cancer Research Communications·2022· 39 citedOpen Access
Direct control of CAR T cells through small molecule-regulated antibodies
Nature Communications·2021· 47 citedOpen Access
Abstract 3239: SMIC CAR T cells: CAR T with temporally-controlled, programmable cytokine signaling outputs
Cancer Research·2020
Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups
Blood·2019· 3 cited
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
Molecular Therapy·2019· 156 citedOpen Access
ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
Blood·2018· 16 cited
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Scientific Reports·2018· 33 citedOpen Access
Abstract LB-182: Differential modulation of the PD-1 pathway impacts the anti-tumor activity of CAR T cells
Cancer Research·2017
page 1 of 2Next →

Frequent Co-authors

Barbra J. Sasu(14), Javier Chaparro‐Riggers(10), Thomas Van Blarcom(9), Janette Sutton(8), Spencer Park(8), Regina Lin(8), Matthew F. Krummel(7), Zea Melton(7), Erez Raz(6), Cesar Sommer(6), Andrew R. Nager(6), Siler H. Panowski(6), Cecilia Lay(5), Yi Zhang(5), Hajime Hiraragi(5), Amanda E. Nelson(4), Trevor Bentley(4), Julien Valton(4), Q. David Walker(4), Purnima Sundar(4)